Sr Computational Geneticist

Our group is looking for an enthusiastic Senior Computational Geneticist with demonstrated successful science leadership and strong track record of innovation and research accomplishments. Well-built expertise on the mechanisms and biology of solid tumors and hematologic malignancies aimed to discover and characterize new oncogenic driver and tumor protective genetic variants. The ideal candidate will possess a deep-knowledge of cell intrinsic and cell extrinsic mechanisms directed to discover identify, functionally characterize and target germline and somatic mutations linked with cancer transformation. Experience in the integrative analysis of multiomic platforms towards prioritizing high-value variants of interest and the mechanistic characterization of cancer-associated mutations is a plus. Ideal candidate will be highly skilled in integrating cancer-specific mutational variant identification with mechanistic and functional validation studies; excel in fast-paced and highly collaborative environments, including other therapeutic areas, technology development teams and core groups and show excellent communication (written/verbal), presentation and leadership skills.

A typical day in this role may include the following:

• Lead independent projects aimed to integrate novel cancer risk-associated germline variant and somatic mutation identification with therapeutic strategies and mechanistic validation.
• Apply biological insights to prioritize genetic discoveries in founder and other populations for functional follow-up.
• Catalogue hits associated to epigenetic, cells signaling, DNA damage and immune surveyance mechanisms to uncover potential for therapeutic targeting of premalignant states and chemo-resistant tumors.
• Manage the implementation of therapeutic strategies and experimental validation of newly identified oncogenic associated driver mutations.
• Work with multidisciplinary teams to nominate and design functional experiments to follow-up on interesting hits.
• Oversee phenotypic characterization of oncogenic and disease-specific variants.

• Actively identify and engage potential new external collaborators with access to well-phenotyped populations.

• Responsible for authoring documents to be published in patent applications, external conference posters and journal articles.

• Lead collaborations with international institutions contributing data and ideas.

• Synthesize results across experiments and programs in presentations to colleagues and cross-functional teams.

This role may be for you if:

• Highly motivated to find and develop new therapeutic targets for effective cancer treatment.

• Problem-solving skills and capability to create new tools to address complex biological questions.

• Proficient leadership of simultaneous projects, excels working in fast-paced and highly collaborative environments.

• Highly skilled in critical thinking and efficient multi-tasking.

• Creative and result-driven, critical thinker and quick learner.

• Up-to-date knowledge of scientific literature.

• Strong expertise in the design and implementation of new protocols, technical reports and scientific writing.

• Skilled in designing, preparing and delivering presentations, reports of literature and project progress reports to a multidisciplinary audience.

To be considered for this role,

You must have a PhD in molecular oncology with 1-3 years’ experience in tumor biology. Understanding of biology to integrate and leverage diverse datasets to identify interesting variants, genes, and genotype-phenotype associations. Extensive experience with molecular characterization and functional studies geared towards elucidating gene functions and the mechanistic basis for genetic associations. This includes ability to interpret genome-wide localization of oncogenic variants to identify mechanisms of gene modulation, genome-wide CRISPR screening to identify synthetic lethal variants or resistance-associated variants (from design to final computational analysis), single-cell sequencing and integrative analyses of NGS-based epigenomics. Demonstrated experience with genetically engineered mouse models (knock-in, knock-out, reporter and bioluminiscent mice), design and implementation of murine in vivo cancer modeling, stem cell transplantation, human primary-derived organoids, multi-color fluorescence-activated cell sorting (FACS), isolation and characterization of multiprotein complexes, gain of function and loss of function cellular assays (CRISPR knockout, RNAi, reversible degradation tag (dTAG) systems) and ‘classic wetlab’ assays (WB, IP, tissue culture and in vitro pharmacology). Expertise in the design and interpretation of in vivo oncogenic and therapeutic efficacy studies in both immunocompetent and immunocompromised mouse models of hematological malignancies and solid tumors. Proven record of authorship in high impact scientific articles published in international peer-reviewed journals.